Just a few months ago Adam was calling results "meaningless" and calling AVXL investors "suckers." Where ss this pathetic excuse for a human being today?
The Raymond James recommendation means absolutely nothing until management starts to deliver. So far, management has failed miserably!
Love all the thumbs down I got on this post by those of you who have blinders on. Since my post on June 24, NVIV is down another 9%. Mark my words - a close below $5.00 takes this to the $2's....
I give you all a fair warning. NVIV will generate a double bottom sell signal with a close below $5.00, likely taking it to the $2.50 level. Management sucks. They've done an absolute horrid job for their shareholders. Expect lawsuits. Time is money and this drip, drip, drip to the downside with no additional patient enrollments says about all that needs to be said. Prepare for NVIV share price to be cut in half.
Is this the best they can do - giving us old news? Where's the next patient? At the current rate of enrollment it will take another two years to reach patient 20.
It took a few more days than expected but here we are now below $6. Support is at $4.50 which is where this company pump began in late February.
And just how can the fundamentals remain "in tact?" Just think how much revenue the scaffold would generate for the company with 8 implants over a 20 month period!!
"Its performance is pretty damn weak"..... man is that a gross understatement - down 72% since July 2013.
Invivo Therapeutics files $150M mixed securities shelf NVIV - The Fly
15 mins ago - Invivo Therapeutics files $150M mixed securities shelf ... 09. Jun. 20. Jun. 2016-06-09 16:22:56NVIV .....
Today's print of $5.41 is a new low for this leg down that began 60 days ago. Frankly, I do not see any catalyst that can turn us around. The painstakingly slow rate of enrollment is killing NVIV and it doesn't speak well for the marketability of the scaffold. Just my opinion but there is no way the scaffold will be approved short of the agreed to 20 patient trial and at the current rate of enrollment, it will take another two years before the 20th patient is enrolled.
When you get placed on ignore for stating that NVIV has lost $160M in market cap in the last 60 days,I guess that means that some on this board actually love losing money! Unbelievable!
I reiterate 100 fold your comments. The vast majorigy of NVIV investors have lost money in a very big way. We all got screwed and shame on us. With only 8 patients enrolled, it will be a cold day in %$## before they expand into the UK and Canada. Mark my words - based on the way this thing has been trading, it's headed to a new 52-week low below $3.50.
Since NVIV topped out at $10.38 two short months ago, NVIV investors have lost a total of $160 Million. While NVIV continues to fall like a hot knife through butter, many of you here continue to buy. Green closes like yesterday (which are few and far between) pull suckers in thinking this thing will finally trade higher only to see it the very next day set a lower low. Something is wrong. Something is totally flawed - maybe it's the snail's pace of enrollments that if they do not pick up will destroy any financial models. Maybe it's incompetent management. Pick your Poisson. The run to $10+ started from the $4's and at this rate it will only take a couple more days before we return to the $4's once again. Cograts to management for losing $160M in market cap over the last 60 days!!!!
I was told by investor relations that Perrin's base salary is $421,395 plus option awards of $1,083,088 plus $215,000 Non-Equity Incentive Plan Compensation plus Other Compensation $200,618 = $1,920,101 and that his options would be totally worthless. Based on this comment it is obvious the folks at NVIV are more concerned about themselves than they are their shareholders. I reminded IR that NVIV stock has now lost nearly $150M in market cap since the Raymond James secondary. Losing $150M to bring in $30M in cash is extremely difficult to rationalize!
Perrin needs to be fired - end of discussion. No one has yet to give a legitimate answer as to why it's taking so long to enroll patients. The company needs to dramatically speed up enrollments to gain credibility that the device can find a big enough market out there once it is approved. Otherwise, this stock is headed for new 52-week lows.
The rise to $10 started from the $4's. Looks like that's where we're headed back to. For all of you who are pleased with the way Perrin has decreased shareholder value, please be sure to send him a box of chocolates.
Your statement concerning near term share appreciation is totally inaccurate and you know it! I do agree with you in that management has made progress although it is way too slow....8 patient enrollments in 18 months simply won't cut it. The slow rate of enrollment is likely the main issue with the stock's poor performance. If you have bought this stock and held it literally most any time over the last five years, you are down SIGNIFICANTLY on your investment. Would you like the numbers - both long-term and short-term?...5 year performance down 19%; 3 year performance down 36%; 2 year performance down 22%; one year performance down 50%; last two month performance down 38%; and finally.... down 71% from all-time high of less than two years ago. As it relates to Perrin's pay, I can name you several dozen other CEO's in the same sector whose pay is less than half of what Perrin makes and whose stock has performed 10 times better.... just on is SUPN. The SUPN CEO makes $916k and the market cap of SUPN is $833M versus a market cap for NVIV of $194M. When SUPN first went public back in 2012 its stock was priced at $4. Four years later its stock is priced near $17 and its stock is up 325%. These are the facts and I'll be more than happy to provide you with dozens of other examples. BOTTOM LINE - Mark Perrin is over paid and taking a pay raise - particularly based on the lack of performance of his stock is a slap in the face of retail shareholders. Since Perrin took his pay raise, our stock has lost $100 million in market cap - an absolutely pathetic disconnect with the retail shareholders who have lost their %$% - short term, medium term and long term!!!! I rest my case.
Perrin had it all planned..... Having a preplanned secondary at $7.50, he releases a bevy of positive press releases to drive his stock over the $10 level. He then announces the secondary and gives himself a fat pay raise, making $2M annually, while every investor alive got the shaft. Since the secondary his company's stock has lost $100 million in market cap and his shareholders are sucking wind but why should he care? He's got his fat paycheck....an absolute disgrace!!!